Anil A. Joy

7.0k total citations · 2 hit papers
146 papers, 4.1k citations indexed

About

Anil A. Joy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Anil A. Joy has authored 146 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Oncology, 61 papers in Pulmonary and Respiratory Medicine and 24 papers in Cancer Research. Recurrent topics in Anil A. Joy's work include Advanced Breast Cancer Therapies (30 papers), HER2/EGFR in Cancer Research (30 papers) and Cancer Treatment and Pharmacology (29 papers). Anil A. Joy is often cited by papers focused on Advanced Breast Cancer Therapies (30 papers), HER2/EGFR in Cancer Research (30 papers) and Cancer Treatment and Pharmacology (29 papers). Anil A. Joy collaborates with scholars based in Canada, United States and France. Anil A. Joy's co-authors include John R. Mackey, Lee W. Jones, Carol E. Cass, Stewart M. Hamilton, David L. Bigam, Bryan J. Dicken, Mark J. Haykowsky, Neil D. Eves, Kerry S. Courneya and Carolyn J. Peddle‐McIntyre and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Anil A. Joy

138 papers receiving 4.0k citations

Hit Papers

Gastric Adenocarcinoma 2005 2026 2012 2019 2005 2019 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gastric Adenocarcinoma
    2005 547 citations Carol E. Cass, John R. Mackey et al. profile →
  2. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
    2019 286 citations Hope S. Rugo, Richard S. Finn et al. Breast Cancer Research and Treatment profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anil A. Joy Canada 31 2.4k 1.9k 729 621 481 146 4.1k
Olivier Mir France 43 2.9k 1.2× 2.8k 1.4× 1.2k 1.6× 610 1.0× 760 1.6× 287 6.4k
Nicholas G. Zaorsky United States 43 2.5k 1.0× 3.1k 1.6× 827 1.1× 659 1.1× 876 1.8× 229 6.7k
Jame Abraham United States 33 2.0k 0.8× 821 0.4× 619 0.8× 810 1.3× 700 1.5× 168 4.1k
Pere Gascón Spain 39 3.0k 1.3× 1.0k 0.5× 1.2k 1.6× 613 1.0× 747 1.6× 163 5.8k
Frans Erdkamp Netherlands 26 2.7k 1.1× 1.3k 0.7× 572 0.8× 562 0.9× 377 0.8× 82 3.7k
James L. Wade United States 45 4.3k 1.8× 2.0k 1.0× 1.3k 1.8× 1.3k 2.1× 796 1.7× 153 7.6k
James A. Kaye United States 38 1.2k 0.5× 937 0.5× 613 0.8× 569 0.9× 823 1.7× 169 5.3k
Christina Lacchetti United States 34 3.9k 1.6× 1.4k 0.7× 648 0.9× 644 1.0× 860 1.8× 63 6.8k
Boštjan Šeruga Canada 34 4.4k 1.9× 1.8k 1.0× 1.2k 1.6× 1.6k 2.6× 809 1.7× 124 7.4k
Randolph S. Marks United States 41 2.7k 1.1× 2.8k 1.5× 1.4k 2.0× 518 0.8× 446 0.9× 121 5.9k

Countries citing papers authored by Anil A. Joy

Since Specialization
Citations

This map shows the geographic impact of Anil A. Joy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anil A. Joy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anil A. Joy more than expected).

Fields of papers citing papers by Anil A. Joy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anil A. Joy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anil A. Joy. The network helps show where Anil A. Joy may publish in the future.

Co-authorship network of co-authors of Anil A. Joy

This figure shows the co-authorship network connecting the top 25 collaborators of Anil A. Joy. A scholar is included among the top collaborators of Anil A. Joy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anil A. Joy. Anil A. Joy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McNeely, Margaret L., Shirin M. Shallwani, Christopher M. Sellar, et al.. (2025). Role of Qualified Exercise Professionals in Medical Clearance for Exercise: Alberta Cancer Exercise Hybrid Effectiveness-Implementation Study. Cancers. 17(17). 2873–2873.
2.
McNeely, Margaret L., Shirin M. Shallwani, Christopher M. Sellar, et al.. (2025). Baseline Characteristics of Participants in the Alberta Cancer Exercise Hybrid Effectiveness–Implementation Study: A Wake-Up Call for Action. Cancers. 17(5). 772–772. 1 indexed citations
3.
Cao, Jeffrey, Jean-François Boileau, Karen A. Gelmon, et al.. (2024). Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer. Current Oncology. 31(11). 7226–7243. 2 indexed citations
4.
Brezden‐Masley, Christine, Anil A. Joy, Sandeep Sehdev, et al.. (2023). Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm. Therapeutic Advances in Medical Oncology. 15. 2620176–2620176. 8 indexed citations
5.
Silva, Bruna Ramos da, Amy A. Kirkham, Katherine L. Ford, et al.. (2023). Time-Restricted Eating in Breast Cancer Survivors: Effects on Body Composition and Nutritional Status. Nutrition and Cancer. 75(5). 1309–1314. 3 indexed citations
6.
McNeely, Margaret L., Christopher M. Sellar, Edith Pituskin, et al.. (2022). Feasibility of Implementing Cancer-Specific Community-Based Exercise Programming: A Multi-Centre Randomized Trial. Cancers. 14(11). 2737–2737. 7 indexed citations
7.
Rayson, Daniel, Sonal Gandhi, Anil A. Joy, et al.. (2022). Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Current Oncology. 29(12). 9891–9895. 2 indexed citations
8.
Zhu, Zhongyi, Weiwei Wang, Lin Feng, et al.. (2021). Genome profiles of pathologist-defined cell clusters by multiregional LCM and G&T-seq in one triple-negative breast cancer patient. Cell Reports Medicine. 2(10). 100404–100404. 6 indexed citations
9.
Rugo, Hope S., Richard S. Finn, Véronique Dièras, et al.. (2019). Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Research and Treatment. 174(3). 719–729. 286 indexed citations breakdown →
10.
Awan, Arif, Andrew Robinson, Carol Stober, et al.. (2019). A prospective, multicentre, randomized trial comparing vascular access strategies for patients receiving non-trastuzumab containing chemotherapy for early stage breast cancer. Annals of Oncology. 30. iii66–iii67. 1 indexed citations
11.
Joy, Anil A., et al.. (2018). Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines. Current Oncology. 25(11). 131–141. 32 indexed citations
12.
Fernandes, Ricardo, Sasha Mazzarello, Anil A. Joy, et al.. (2018). Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study. Supportive Care in Cancer. 26(9). 3073–3081. 14 indexed citations
13.
Zhu, Xiaofu & Anil A. Joy. (2017). Targeting HER2 in Advanced Breast Cancer. Methods in molecular biology. 1652. 63–77. 4 indexed citations
14.
15.
16.
17.
Sawyer, Michael B., Edith Pituskin, Sambasivarao Damaraju, et al.. (2015). A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer. Clinical Breast Cancer. 16(2). 139–144.e3. 17 indexed citations
18.
Chu, Michael P., Sunita Ghosh, Carole Chambers, et al.. (2014). Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 16(1). 33–39. 80 indexed citations
19.
Verma, Sunil, Anil A. Joy, Daniel Rayson, et al.. (2013). HER Story: The Next Chapter in HER-2-Directed Therapy for Advanced Breast Cancer. The Oncologist. 18(11). 1153–1166. 11 indexed citations
20.
Jones, Lee W., et al.. (2009). Exercise therapy across the lung cancer continuum. Current Oncology Reports. 11(4). 255–262. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Olivier Mir Breakdown of academic impact, for papers by Nicholas G. Zaorsky Breakdown of academic impact, for papers by Jame Abraham Breakdown of academic impact, for papers by Pere Gascón Breakdown of academic impact, for papers by Frans Erdkamp Breakdown of academic impact, for papers by James L. Wade Breakdown of academic impact, for papers by James A. Kaye Breakdown of academic impact, for papers by Christina Lacchetti Breakdown of academic impact, for papers by Boštjan Šeruga Breakdown of academic impact, for papers by Randolph S. Marks
Rankless by CCL
2026